



Clinical trial results:

An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Summary

EudraCT number	2018-004392-12
Trial protocol	GB DE FR BE ES NL DK
Global end of trial date	10 November 2021

Results information

Result version number	v1 (current)
This version publication date	22 October 2022
First version publication date	22 October 2022

Trial information

Trial identification

Sponsor protocol code	CIDP04
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04051944
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	UCB Biopharma SRL
Sponsor organisation address	Allée de la Recherche 60, Brussels, Belgium, 1070
Public contact	Clin Trial Reg & Results Disclosure, UCB BIOSCIENCES GmbH, clinicaltrials@ucb.com
Scientific contact	Clin Trial Reg & Results Disclosure, UCB BIOSCIENCES GmbH, clinicaltrials@ucb.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	31 January 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	10 November 2021
Global end of trial reached?	Yes
Global end of trial date	10 November 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Assess long-term safety and tolerability of rozanolixizumab in participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Protection of trial subjects:

During the conduct of the study all participants were closely monitored.

Background therapy:

Background therapy as permitted in the protocol.

Evidence for comparator:

Not applicable

Actual start date of recruitment	21 August 2019
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy, Safety
Long term follow-up duration	19 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 4
Country: Number of subjects enrolled	Denmark: 2
Country: Number of subjects enrolled	France: 2
Country: Number of subjects enrolled	Germany: 2
Country: Number of subjects enrolled	Netherlands: 1
Country: Number of subjects enrolled	United Kingdom: 1
Country: Number of subjects enrolled	United States: 9
Worldwide total number of subjects	21
EEA total number of subjects	11

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	14
From 65 to 84 years	7
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study started to enroll study participants in Aug 2019 and concluded in Nov 2021.

Pre-assignment

Screening details:

Participant Flow refers to Enrolled Set. Participants from CIDP01 (NCT03861481) who had completed Treatment Period without a relapse of CIDP were directly enrolled into this study. Newly treated participants are participants treated with placebo in parent study. Previously treated participants are participants treated with RLZ in parent study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Rozanolixizumab (Newly Treated)

Arm description:

Participants received rozanolixizumab Dose A as a subcutaneous infusion once weekly up to Week 76.

Arm type	Experimental
Investigational medicinal product name	Rozanolixizumab
Investigational medicinal product code	UCB7665
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received rozanolixizumab Dose A at prespecified time points.

Arm title	Rozanolixizumab (Previously Treated)
------------------	--------------------------------------

Arm description:

Participants received rozanolixizumab Dose A as a subcutaneous infusion once weekly up to Week 76.

Arm type	Experimental
Investigational medicinal product name	Rozanolixizumab
Investigational medicinal product code	UCB7665
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received rozanolixizumab Dose A at prespecified time points.

Number of subjects in period 1	Rozanolixizumab (Newly Treated)	Rozanolixizumab (Previously Treated)
Started	11	10
Completed	3	6
Not completed	8	4
Consent withdrawn by subject	2	2
Adverse event, non- fatal	1	1
Study ending	1	1
Early study termination by participant	1	-
Lack of efficacy	3	-

Baseline characteristics

Reporting groups

Reporting group title	Rozanolixizumab (Newly Treated)
Reporting group description: Participants received rozanolixizumab Dose A as a subcutaneous infusion once weekly up to Week 76.	
Reporting group title	Rozanolixizumab (Previously Treated)
Reporting group description: Participants received rozanolixizumab Dose A as a subcutaneous infusion once weekly up to Week 76.	

Reporting group values	Rozanolixizumab (Newly Treated)	Rozanolixizumab (Previously Treated)	Total
Number of subjects	11	10	21
Age Categorical Units: participants			
<=18 years	0	0	0
Between 18 and 65 years	8	6	14
>=65 years	3	4	7
Age Continuous Units: years			
arithmetic mean	59.8	59.1	
standard deviation	± 5.1	± 15.9	-
Sex: Female, Male Units: participants			
Female	4	6	10
Male	7	4	11

End points

End points reporting groups

Reporting group title	Rozanolixizumab (Newly Treated)
Reporting group description:	
Participants received rozanolixizumab Dose A as a subcutaneous infusion once weekly up to Week 76.	
Reporting group title	Rozanolixizumab (Previously Treated)
Reporting group description:	
Participants received rozanolixizumab Dose A as a subcutaneous infusion once weekly up to Week 76.	

Primary: Number of participants with treatment-emergent adverse event (TEAEs)

End point title	Number of participants with treatment-emergent adverse event (TEAEs) ^[1]
End point description:	
An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product, which does not necessarily had a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE was defined as any event that was not present prior the first administration of investigational medicinal product (IMP) in CIDP04 study or any unresolved event already present before the first administration of IMP in CIDP04 study that worsened in intensity following exposure to treatment until 8 weeks following the last administration of IMP in CIDP04 study. The Safety Set (SS) consisted of all enrolled study participants who were administered at least one dose of rozanolixizumab in CIDP04.	
End point type	Primary
End point timeframe:	
From Baseline until Follow-Up Visit (up to Week 84)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized in tables as descriptive statistics only.

End point values	Rozanolixizumab (Newly Treated)	Rozanolixizumab (Previously Treated)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	10		
Units: participants	10	10		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From Baseline until Follow-Up Visit (up to Week 84)

Adverse event reporting additional description:

A TEAE was defined as any event that was not present prior the first administration of IMP in CIDP04 study or any unresolved event already present before the first administration of IMP in CIDP04 study that worsened in intensity following exposure to treatment until 8 weeks following the last administration of IMP in CIDP04 study.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.0
--------------------	------

Reporting groups

Reporting group title	Rozanolixizumab (Newly Treated)
-----------------------	---------------------------------

Reporting group description:

Participants received rozanolixizumab Dose A as a subcutaneous infusion once weekly up to Week 76.

Reporting group title	Rozanolixizumab (Previously Treated)
-----------------------	--------------------------------------

Reporting group description:

Participants received rozanolixizumab Dose A as a subcutaneous infusion once weekly up to Week 76.

Serious adverse events	Rozanolixizumab (Newly Treated)	Rozanolixizumab (Previously Treated)	
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 11 (18.18%)	2 / 10 (20.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant melanoma			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Chronic inflammatory demyelinating polyradiculoneuropathy			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sensory loss			

subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Rozanolixizumab (Newly Treated)	Rozanolixizumab (Previously Treated)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 11 (90.91%)	9 / 10 (90.00%)	
Investigations			
Blood immunoglobulin G decreased			
subjects affected / exposed	4 / 11 (36.36%)	4 / 10 (40.00%)	
occurrences (all)	10	8	
Injury, poisoning and procedural complications			
Muscle strain			
subjects affected / exposed	1 / 11 (9.09%)	2 / 10 (20.00%)	
occurrences (all)	1	2	
Fall			
subjects affected / exposed	0 / 11 (0.00%)	2 / 10 (20.00%)	
occurrences (all)	0	4	
Nervous system disorders			
Headache			
subjects affected / exposed	4 / 11 (36.36%)	1 / 10 (10.00%)	
occurrences (all)	7	5	
Neuralgia			
subjects affected / exposed	1 / 11 (9.09%)	2 / 10 (20.00%)	
occurrences (all)	1	2	
Sensory loss			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	
occurrences (all)	3	0	
General disorders and administration			

site conditions Pyrexia subjects affected / exposed occurrences (all) Fatigue subjects affected / exposed occurrences (all) Peripheral swelling subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2 3 / 11 (27.27%) 3 1 / 11 (9.09%) 1	0 / 10 (0.00%) 0 3 / 10 (30.00%) 4 1 / 10 (10.00%) 1	
Gastrointestinal disorders Constipation subjects affected / exposed occurrences (all) Diarrhoea subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0 1 / 11 (9.09%) 2	2 / 10 (20.00%) 2 1 / 10 (10.00%) 1	
Respiratory, thoracic and mediastinal disorders Rhinorrhoea subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	1 / 10 (10.00%) 2	
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	1 / 10 (10.00%) 1	
Musculoskeletal and connective tissue disorders Joint swelling subjects affected / exposed occurrences (all) Muscle spasms subjects affected / exposed occurrences (all) Muscular weakness subjects affected / exposed occurrences (all) Back pain	1 / 11 (9.09%) 1 0 / 11 (0.00%) 0 2 / 11 (18.18%) 4	2 / 10 (20.00%) 2 2 / 10 (20.00%) 2 0 / 10 (0.00%) 0	

subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	1 / 10 (10.00%) 1	
Infections and infestations			
Influenza			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	
occurrences (all)	2	0	
Urinary tract infection			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	
occurrences (all)	2	0	
Upper respiratory tract infection			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	
occurrences (all)	2	0	
Nasopharyngitis			
subjects affected / exposed	2 / 11 (18.18%)	2 / 10 (20.00%)	
occurrences (all)	2	2	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
12 July 2019	<p>The purpose of this substantial protocol amendment was to provide clarification on the dose of IMP administered (including an allowance of $\pm 10\%$ compared to the target Dose A arm), as well as a flexible infusion rate. Sensitivity analyses were introduced to account for deviation outside the 10% target dosage and the descriptive analyses will inform about actual doses administered to the study participants. Updates to the status of the other rozanolixizumab studies had been included. The predominance of objective criteria over the investigator's judgment had been confirmed for the assessment of CIDP relapse. The timeframe of expected use of contraception poststudy completion had been extended to 90 days in view of the probable half-life of rozanolixizumab. Exclusion Criterion had been extended to prediabetic condition. The expectation with regards to the use of cannabidiols and medicinal marijuana had been clarified in the concomitant medication section. The protocol amendment confirmed the expectation of a single rater for the Inflammatory Neuropathy Cause and Treatment (INCAT) assessment to ensure consistency of the rating during the study. The exit interview assessment had been removed from the follow-up study; this allowed UCB to confirm the adequacy of this tool using data collected in CIDP01 before extending its use in another study. Safety reporting procedures had been updated to align with most current UCB practices.</p>
16 March 2020	<p>The purpose of this substantial protocol amendment was to assess the safety and key efficacy of rozanolixizumab during an optional additional treatment period (Treatment Period Part 2) of up to 52 weeks (or until an Access Program or equivalent was available for rozanolixizumab, whichever came first) on the basis of each study participant's individual benefit-risk assessment at the end of the first 24-week Treatment Period. This amendment was the opportunity to update the new legal entity of UCB effective since Dec 2019. Additional wording pertaining study participants being able to self-administer IMP after appropriate training had been included. One exclusion criterion had been clarified. The management of hypogammaglobulinemia had been adjusted for better control. An additional interim analysis had been added at the time of lock of the parent study and another at the end of the first Treatment Period (24 weeks) matching the original timepoint of results availability.</p>

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported